Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:42:53.813Z.
Calculation as of: 2026-10-06T19:42:53.813Z.
Quote observation: 2026-10-06T19:20:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a0cb01cc31f7f7a1ab27ea5f4e27b2bab80fdffd2dde3b1d08905865647984d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Paranovus Entertainment Technology Ltd.
Market Cap
$3.32M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.12M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Paranovus Entertainment Technology Ltd. (PAVS) | $3.32M | N/A | N/A | N/A | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.24M | N/A | N/A | N/A | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $3.20M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.15M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 0.09% | 0.09% | 0.09% |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.49M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.12M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.55M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
